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Background: Acquired resistance to cisplatin treatment is a caveat when treating patients with non-
small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). Ceramide increases in
response to chemotherapy, leading to proliferation arrest and apoptosis. However, a tumour stress
activation of glucosylceramide synthase (GCS) follows to eliminate ceramide by formation of glyco-
sphingolipids (GSLs) such as globotriaosylceramide (Gb3), the functional receptor of verotoxin-1.
Ceramide elimination enhances cell proliferation and apoptosis blockade, thus stimulating tumor
progression. GSLs transactivate multidrug resistance 1/P-glycoprotein (MDR1) and multidrug
resistance-associated protein 1 (MRP1) expression which further prevents ceramide accumulation
and stimulates drug efﬂux. We investigated the expression of Gb3, MDR1 and MRP1 in NSCLC and
MPM cells with acquired cisplatin resistance, and if GCS activity or MDR1 pump inhibitors would
reduce their expression and reverse cisplatin-resistance.
Methods: Cell surface expression of Gb3, MDR1 and MRP1 and intracellular expression of MDR1 and
MRP1 was analyzed by ﬂow cytometry and confocal microscopy on P31 MPM and H1299 NSCLC cells
and subline cells with acquired cisplatin resistance. The effect of GCS inhibitor PPMP and MDR1 pump
inhibitor cyclosporin A for 72 h on expression and cisplatin cytotoxicity was tested.
Results: The cisplatin-resistant cells expressed increased cell surface Gb3. Cell surface Gb3 expression of
resistant cells was annihilated by PPMP whereas cyclosporin A decreased Gb3 and MDR1 expression in
H1299 cells. No decrease of MDR1 by PPMP was noted in using ﬂow cytometry, whereas a decrease of
MDR1 in H1299 and H1299res was indicated with confocal microscopy. No certain co-localization of
Gb3 and MDR1 was noted. PPMP, but not cyclosporin A, potentiated cisplatin cytotoxicity in all cells.
Conclusions: Cell surface Gb3 expression is a likely tumour biomarker for acquired cisplatin resistancelsevier Inc. This is an open access article under the CC BY-NC-ND license
/4.0/).
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could explain the aggressiveness of NSCLC and MPM. Therapy with GCS activity inhibitors or toxin
targeting of the Gb3 receptor may substantially reduce acquired cisplatin drug resistance of NSCLC and
MPM cells.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Non-small cell lung cancer (NSCLC) and malignant pleural
mesothelioma (MPM) are aggressive malignant tumors associated
with dismal patient survival. Chemotherapy with cisplatin is
frequently used for treatment of advanced stages, usually leading
to partial tumor responses or disease stabilization with a slight
increase in patient survival time. Cisplatin acts by forming
platinum-DNA adducts which hinders rapidly dividing cells from
duplicating their DNA for mitosis and activates apoptosis [1,2].
However, a main limitation to the clinical usefulness of cisplatin
treatment is the high incidence of acquired drug-resistance [3,4].
Circumventing cisplatin resistance is therefore of prime impor-
tance in these tumor diseases.
One major mechanism for cisplatin resistance is reduction of
intracellular platinum accumulation [5,6] by either reduced uptake
[7] or increased efﬂux by trans-membrane pumps such as multi-
drug resistance 1/P-glycoprotein (MDR1), which was the ﬁrst
ATP-binding cassette (ABC) protein demonstrated to confer resis-
tance to cancer chemotherapeutics [8–10]. Overexpression of
MDR1 enhances DNA damage repair and reduces apoptosis induc-
tion [11,12]. Other transporter proteins such as multidrug
resistance-associated protein 1 (MRP1) and breast cancer resis-
tance protein (BCRP) have in addition been described to confer
cisplatin resistance. MRP1 also belongs to the ABC transporter
super-family and readily extrude glutathione-S-cisplatin conju-
gates from the cells and is associated with cisplatin resistance [13].
The glycosphingolipids (GSLs) are a subtype of glycolipids that
are synthesized by glycation of ceramide. Ceramide increases in
response to chemotherapy, leading to proliferation arrest and
apoptosis. However, a tumour cell reaction follows to eliminate
ceramide by glucosylceramide synthase (GCS) conversion of
ceramide to glucosylceramide and formation of GSLs. Persistent
GCS activity leads to ceramide reduction and stimulated cell
proliferation and blocked apoptosis, thus stimulating tumor
progression [14].
Lactosylceramide, Galβ1,4Glcβ1Cer (LacCer), is the common
synthetic precursor to the majority of GSL found in vertebrates.
Gb3 synthase acts on LacCer to produce globotriaosylceramide
(Gb3) [15]. Glucosylceramide is required to maintain Gb3 in
plasma membrane lipid rafts [16]. Gb3 is expressed in several
human malignancies such as lymphoma [17], in various solid
tumors including breast cancer [18] and testicular carcinoma [19]
but not in non-malignant tissue except in the vasculature of some
tissues. Gb3 expression in colorectal cancer correlates with
invasiveness and metastatic potential [20]. Elevated levels of
Gb3 have also been seen in drug-resistant cancers and cell lines.
The MDR1 drug pump is Golgi-associated and is a prerequisite for
neutral GSL biosynthesis [21] as it provides glycosylceramide as a
substrate for luminal glycosyl transferases including GCS [22].A functional dependency between Gb3 and MDR1 in plasma
membrane lipid rafts has been suggested [23–25] possibly
through the GCS-upregulated MDR1 expression [26]. Cell surface
MDR1 has been found to partially co-localize with Gb3 in MDR1-
transfected canine kidney cells [21].
The relationship between acquired cisplatin resistance and the
expression of MDR1 and MRP1-proteins in relation to Gb3
expression or inhibition of GCS activity has not been examined
in NSCLC/MPM. Our previous studies suggested an interrelation-
ship between cell multidrug-resistance and plasma membrane
Gb3 expression in cultured NSCLC and MPM cells with or without
acquired cisplatin resistance. The studies also suggested that
cisplatin preferentially eradicates MPM cells with low Gb3
expression. The GCS activity inhibitor DL-threo-1-phenyl-2-pal-
mitoylamino-3-morpholino-1-propanol (PPMP), or a subtoxic
concentration of the Gb3-receptor binding bacterial toxin
verotoxin-1, resensitized Gb3-overexpressing cisplatin-resistant
NSCLC and MPM subline cells to cisplatin [27].
We hypothesized that Gb3, MDR1 and possibly MRP1 would be
co-expressed and co-localized in MPM and NSCLC, and that GCS
activity inhibition would confer inhibition not only of Gb3, but
also of the expression of MDR1 and/or MRP1 proteins and re-
sensitize resistant tumour cells to cisplatin cytotoxicity. To test
this hypothesis, we used ﬂow cytometry and confocal microscopy
to analyze cell-surface as well as intracellular expression of Gb3,
MDR1 and MRP1 and to study if inhibitors of GCS or MDR1
activity would affect their expression in cultured NSCLC and MPM
cells with or without acquired cisplatin resistance and re-sensitize
the resistant cells to cisplatin.2. Materials and methods
2.1. Cell lines and cell culture
Two human cell lines were used: the MPM cell line P31 [28], and
the NSCLC cell line H1299 (American Type Culture Collection,
CRL-5803, (Manassas, VA, USA) and their corresponding
cell sublines with acquired-cisplatin resistance (P31res and
H1299res). The cisplatin-resistant cell sublines were created by
culturing the parental cells in medium with gradually increasing
concentrations of cisplatin; the LD50 concentration after 72 h
incubation with cisplatin needed for the acquired cisplatin-
resistant sublines was approx. 4 times as high as for the parental
cell line. The cells were maintained under standard cell culture
conditions, grown as monolayer culture in Eagle's MEM in Earl's
salt (Gibco Ltd, Paisley, Scotland, UK) supplemented by 10% fetal
bovine serum (Biochrom KG, Berlin, Germany) and 200 mmol/L
L-glutamine. They were maintained at 37 1C in a humidiﬁed
atmosphere containing 5% CO2. The maintenance concentration
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H1299res cell sublines.
DL-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propa-
nol (PPMP) (Sigma-Aldrich, St Louis, MO, USA), a chemical
inhibitor of glucosylceramide synthase activity, and cyclosporin
A (Sigma-Aldrich), an inhibitor of MDR1 pump activity, were used
to deplete Gb3 expression by culturing cells with 2 mmol/L PPMP
or 10 mmol/L cyclosporin A for 72 h, respectively.
2.2. Flow cytometry analysis
P31, P31 res, H1299 and H1299res cells were trypsinized, suspended
in PBS and washed with PBS twice. Fixed and permeabilised cells for
total, mainly intracellular, expression, and un-ﬁxed and non-
permeabilised cells for cell surface expression were obtained by
incubating with or without 2% formaldehyde for 1 h in room
temperature, followed by one wash with 2% BSA in PBS, with or
without permeabilisation in 0.5% Triton X-100 and 0.1% sodium citrate
at 4 1C for 10min, and ﬁnally washed twice with PBS-BSA. Cells were
then stained with rat anti-Gb3 IgM 1:20 (Beckman Coulter Inc., Brea,
CA, USA), mouse anti-MDR1 IgG2A 1:50 (Chemicon Internat., Teme-
cula, MA, USA) or mouse anti-MRP1 IgG2A 1:40 (R&D Systems Inc.,
Minneapolis, MN, USA) primary antibodies. To distinguish from non-
speciﬁc binding, cells were stained with corresponding rat IgM and
mouse IgG2A isotype antibodies (Invitrogen, Carlsbad, CA, USA).
Subsequently, cell pellets were re-suspended and incubated with
Alexa Fluor 488 or 647 –labeled goat anti-rat IgM (1:50, Invitrogen)
and goat anti-mouse IgG2A (Invitrogen) secondary antibodies (1:100)
for 1 h at 4 1C. After washing the cells and centrifuging for 10min,
cells were analyzed with a FACScan ﬂow cytometer (Becton Dickinson
Immunotech Systems, San Jose, CA, USA) on channels FL4 or FL1 and
data was processed using the BD CellQuests software (Becton
Dickinson). After gating out debris and cell aggregates, the data was
dot plotted. The analysis for MDR1 and MRP1 was made separately,
which is why there are more data on Gb3 than MDR1 and MRP1.
2.3. Confocal microscopy analysis of expression and
inhibition of Gb3, MDR1 and MRP1
The four cell line/subline cells were grown on glass cover-slips for a
total of three days, the total number of cells added to each slide were
20,000 for P31, 60,000 for P31res, 10,000 for H1299 and 120,000 for
H1299res. The seeding density for cells growing with cyclosporin A
and PPMP were doubled to achieve similar conﬂuence. Incubation
with isotype or primary antibodies (Gb3, MDR1, MRP1 – see ﬂow
cytometry) at room temperature for 1 h was followed by incubation
with Alexa Fluors -labeled secondary antibodies (see ﬂow cytome-
try) for another hour at room temperature. Photobleaching was
prevented by using ProLongs Gold Anti-fade DAPI (Invitrogen,
Carlsbad, CA, USA) containing 40, 6-diamidino-2-phenylindole (DAPI)
for nuclear staining. Images were acquired using ZEN 2010 imaging
software on a LSM 710 confocal microscope (Carl Zeiss Microscopy
GmbH, Jena, Germany).
Quantitation of the ﬂuorescence intensity of the confocal
microscope images was performed using the Imaris software
(Bitplane, Switzerland). This method allows for determination of
ﬂuorescence intensity in small well-deﬁned volumes (VOI) in
single cells, permitting the comparison of different cells for the
same proteins. VOI represents the number of voxels in the x, y-
and z-dimension, where size and resolution depends on themagniﬁcation, the numerical aperture of the objective lens and
the number of layers deﬁned at the time of confocal data
acquisition. The ﬂuorescence threshold was set against the
ﬂuorescence of isotype antibodies so that only cells with elevated
protein expression were quantiﬁed.2.4. Cell viability assay
A ﬂuorometric method utilizing ﬂuorescein diacetate, FDA,
(Amersham International, Amersham, UK) was used to quantify
viable cells and determine cisplatin (Bristol-Myers Squibb, New
York, NY, USA) sensitivity of all H1299 and P31 cell line/subline
cells in combination with PPMP or cyclosporin A in vitro. Cells (3–
10103) were plated with 100 mL medium in the wells of 96-well
microtiter plates. The plates were ﬁrst incubated at 37 1C for 24 h
with culture medium only, then medium was replaced with fresh
medium, containing LD50 concentrations of cisplatin and/or
2 mmol/L PPMP or 10 mmol/L cyclosporin A for 72 h. Medium
was removed by ﬂicking the plate and wells were washed once
with 200 mL PBS buffer. To each well 100 mL of PBS containing
10 mg/L FDA was added, and the plates incubated for 45 min at
37 1C, followed by ﬂuorescence determination in a ﬂuorometer
(LS 55, Perkin Elmer, MA, USA) using 485 and 538 nm for
excitation and emission, respectively. The combined cytotoxicity
of two drugs incubated simultaneous was compared against a
combination index calculated for an expected additive cytotoxic
effect of the drugs per se.3. Statistics
SPSS 22.0 was used for statistical analysis. Mann–Whitney U-test was
performed. The level of signiﬁcance to reject the null hypothesis was
po0.05. All results are presented as mean72 S.E.M.4. Results
4.1. Flow cytometry analysis of MDR1 and MRP1
expression
4.1.1. Flow cytometry on ﬁxed and permeabilised cells
The distribution of individual cell total (mostly intracellular)
expression of MDR1 and MRP1 was evaluated by FACS analysis
on ﬁxed and permeabilised cells. All parental as well as subline
cells demonstrated a high expression of MDR1 protein, whereas
MRP1 was expressed to a less extent by a high proportion of P31
parental (99%) and subline (79%) cells but less by H1299 parental
(62%) and subline (72%) cells (Table 1).
MRP1 levels were 2.7 to 5.3 times that of the isotype control
and with no apparent mean ﬂuorescence differences between
parental and cisplatin-resistant sublines (Table 1). MDR1 protein
was however expressed to a much higher extent in all cell lines
with ﬂuorescent means 44.0–79.3 times that of the isotype
control, again with no differences between parental and resistant
cells (Table 1).
Incubation of the cells with 2 μmol/L PPMP or 10 μmol/L
cyclosporin A for 72 did not signiﬁcantly affect MDR1 and MRP1
ﬂuorescence of any of the tested cells/subline cells (data not
shown).
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Cell surface expression of Gb3 in relation to MDR1 and MRP1
protein expression was evaluated by FACS analysis on non-ﬁxed
and non-permeabilised cells. Only a small number of cells
expressed cell surface MRP1 protein expression (results not
shown) and further studies of this protein was discontinued.
Gb3 was detected in 25% of the cisplatin-resistant p31res cells and
19% of the cisplatin-resistant H1299res cells (Fig. 1), MDR1 was
detected in 1% and 2% of the cells in resistant sublines (Fig. 2),
respectively. Flow cytometry scattergrams showed a correlated
co-expression of MDR1 and Gb3 only in a small streak of cells in
the upper right ﬂow cytometry quadrant of the resistant cell
sublines (Fig. 1) and at least partly due to unspeciﬁc binding as
the isotype control demonstrated a similar expression pattern.
Incubation of resistant subline cells with 2 μmol/L PPMP for
72 h before FACS analysis reduced the subfraction of cells with
increased Gb3 cell surface expression to 3–8% of all cells whereas
MDR1 expression was largely unaffected (Fig. 1) Incubation with
10 μmol/L cyclosporin A did not affect Gb3 or MDR1 expression in
these cells (Fig. 1).4.1.3. Confocal microscopy analysis of Gb3, MDR1 and MRP1
expression
Laser-scanning confocal microscopy was then used for visualiza-
tion of the distribution and possible co-localization as well as
software quantiﬁcation of Gb3, MDR1 and MRP1 cell surface
overexpression as cells below the isotype antibody limits was
gated away. No expression of MRP1 was noted. There was no sign
of co-localization of Gb3 and MDR1.
Using the Imaris software to objectively quantify the mean
ﬂuorescence intensity of confocal microscopy images of cells with
cell surface Gb3 and MDR1 expression with and without PPMP
and cyclosporin A demonstrated that P31 cells on acquisition of
cisplatin resistance on average expressed extensively more
(po0.001) Gb3 and MDR1 (po0.01) (Fig. 3). The Gb3 expression
of H1299 cells on acquisition of resistance was not affected (p¼N.
S.), whereas MDR1 was markedly increased (po0.001).
Incubation with 10 mmol/L cyclosporin A decreased (po0.01)
MDR1 and Gb3 cell surface mean ﬂuorescence in H1299 parental
cells but did not affect the expression in the other cell lines (Fig. 3).
Incubation with 2 mmol/L PPMP almost eradicated cell surface
Gb3 expression in all cell lines except possibly in P31 parental
cells with already very low Gb3 expression, whereas MDR1
expression was decreased in H1299 (po0.05) and P31res cells
(po0.05) (Fig. 3).4.1.4. Effect of PPMP and cyclosporin A exposure on cisplatin
cytotoxicity
Exposure of all NSCLC and MPM cells (not only the fraction with
increased Gb3 expression) to LD50 concentrations of cisplatin for
72 h demonstrated cytotoxicity to the parental cells and cisplatin-
resistant cell sublines (Fig. 4). The cytotoxicity of 2 mmol/L PPMP
per se reduced cell viability to approx. 80% with the exception of
P31 cells where it was approx. 60% and 10 mmol/L cyclosporin A
per se reduced the viability to 30–60%. The effect of PPMP on
cisplatin cytotoxicity using LD50 concentrations was more than
additive on all parental and sublines cells but not H1299res
subline cells where an approx. additive effect was noted. The
effect of cyclosporin A was additive on all parental and subline
Isotype
Cyclosporin A
PPMP
Control
P31res H1299res
Gb3
M
D
R
1
1±00±0
0±0
1±11±0
1±0
1±10±0
24±0
2±21±0
17±8
3±11±1
23±7
3±11±0
15±7
2±21±1
6±3
2±21±1
1±0
M. Fl.
Gb3: 5±1
MDR1: 13±4
M. Fl.
Gb3: 65±8
MDR1: 17±11
M. Fl.
Gb3: 60±25
MDR1: 26±14
M. Fl.
Gb3: 19±9
MDR1: 30±27
M. Fl.
Gb3: 6±2
MDR1: 17±14
M. Fl.
Gb3: 75±53
MDR1: 32±34
M. Fl.
Gb3: 82±61
MDR1: 42±40
M. Fl.
Gb3: 12±8
MDR1: 41±46
Fig. 1 – Flow cytometry detection of cell surface Gb3 (globotriaosylceramide) and MDR1 (multidrug resistance 1) in cisplatin-
resistant subline (malignant pleural mesothelioma P31res, non-small cell lung cancer H1299res) cells incubated without (control)
or with 10 μmol/L cyclosporin A or 2 μmol/L PPMP for 72 h. Dot plots of ﬂuorescence intensity (x-axis) of FITC-labeled Gb3
antibody plotted against the ﬂuorescence intensity (y-axis) of labeled antibodies to MDR1. Representative results from 3
experiments. Mean proportion71 SD of all positive quadrants is and mean ﬂuorescence (M. Fl.) of Gb3 and MDR1 is included in the
ﬁg. n¼3.
E X P E R I M E N T A L C E L L R E S E A R C H 3 3 6 ( 2 0 1 5 ) 2 3 – 3 2 27cells but not P31 parental cells where cytotoxicity was found to be
more than additive (Fig. 4).5. Discussion
Cell surface Gb3 expression was induced in MPM and NSCLC cell
lines with acquired cisplatin resistance. The glycosphingolipid
synthesis inhibitor PPMP radically decreased the induced cell
surface Gb3 but not MDR1 protein expression and also augmen-
ted cisplatin cytotoxicity of the resistant MPM cell subline. The
results indicate that expression of cell surface Gb3 is a biomarker
of acquired cisplatin resistance in MPM and NSCLC. Perhaps cell
surface Gb3 reﬂects the functional resistance to cisplatin better
than cell surface expression of MDR1. Therapy with GCS inhibitors
reducing ceramide glycosylation or with Gb3 receptor-binding
verotoxin-1 may overcome or reduce acquired cisplatin drug
resistance in NSCLC and MPM [27].Lung cancer is the ﬁrst and second leading cause of cancer-
related death in men and women, respectively [30,31]. The most
common type is non-small cell lung cancer (NSCLC), which
accounts for over 75% of all cases [32]. Malignant pleural
mesothelioma (MPM) is a high mortality malignancy with poor
prognosis partially because of treatment resistance [33]. Treat-
ment options often include platinum-based drugs such as cispla-
tin (cis-diamminedichloroplatinum (II), which is extensively used.
However, the occurrence of inherent resistance and especially,
treatment-induced acquired resistance to cisplatin is a major
clinical problem that undermines the curative potential of the
drug [34].
A well characterized form of drug resistance is due to over-
expression of drug efﬂux pumps, especially MDR1 of the ABC
(ATP-binding cassette) transporter super-family, capable of efﬂux
of many different chemotherapeutic agents, leading to decreased
drug accumulation [6,21]. The importance of ATP-casette protein
efﬂux in cisplatin resistance [35] has however been questioned
H1299
H1299res
-PPMP
P31
-PPMP
P31res
+PPMP
+PPMP
Fig. 2 – Confocal microscopy of extracellular Gb3 (globotriaosylceramide) and MDR1 (multidrug resistance 1) Gb3 (green) and
MDR1 protein (red) expression of malignant pleural mesothelioma cell line P31, non-small cell lung cancer cell line H1299 and
their correspondent resistant sub-lines P31res, and H1299res incubated without or with 2 μmol/L PPMP for 72 h. The nucleus
(blue) was stained with DAPI. Objective lens (63 ) magniﬁcation. Representative results are shown (n¼9).
E X P E R I M E N T A L C E L L R E S E A R C H 3 3 6 ( 2 0 1 5 ) 2 3 – 3 228[7] as speciﬁc MDR1 transport inhibitors were unable to restore
cisplatin accumulation and sensitivity [36].
Ceramide and glycosphingolipids (GSL) are important mole-
cules as they affect cell functions such as apoptosis, proliferation,endocytosis, transport and migration, and thereby regulate tumor
genesis, cancer progression, and cancer treatment efﬁciency [37].
Glucosylceramide synthase (GCS) is a key enzyme for ceramide
glycosylation and GSL synthesis. Following cell stress, such as
***
*** ***
***
***
**
*
***
**
*
Fig. 3 – Quantiﬁcation of cell surface (A) Gb3 (globotriaosylceramide) and (B) MDR1 (multidrug resistance 1) expression in parental
cell lines non-small cell lung cancer cell line H1299 and the malignant pleural mesothelioma cell line P31 as well as their cisplatin-
resistant sublines H1299res and P31res. Quantitation of the ﬂuorescence intensity (voxels) of the confocal microscope images
using the Imaris software (Bitplane, Switzerland). The ﬂuorescence threshold was set against the ﬂuorescence of isotype
antibodies so that only cells with elevated protein expression were quantiﬁed. Mean expression72 S.E.M. from 9 images (taken
from three different experiments, total number of cells was at least 300). Mann–Whitney U-test was used to compare expression
between groups.
nnnpo0.001, nnpo0.01, npo0.05 compared to control.
Fig. 4 – Cell viability assays of exposed cells to LD50 cisplatin, with or without PPMP and cyclosporin A alone or in combination.
Cell viability (ﬂuorescence of FMCA assays – control cells set to 100%) after exposure of malignant pleural mesothelioma cell line
P31 and non-small cell lung cancer cell line H1299 NSCLC cell lines and their cell sublines with acquired cisplatin resistance
(P31res, H1299res) incubated with LD50 cisplatin (1 mg/L for P31 and H1299 cells, 5 mg/L for P31res and H1299res cells without or
with 2 lmol/L PPMP or 10 lmol/L cyclosporin A alone or in combination for 72 h. Arrows on/above histogram bars of drug
combinations denote the expected result of an additive cytotoxic effect when calculating on the effect of the drugs alone. Mean
viability72 S.E.M. (n¼6). Mann–Whitney U-test was used to compare viability between groups.
***po0.001 (compared to control), ¤¤¤ po0.001 (compared to cisplatin and cyclosporin A/PPMP.
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deplete (drug-induced) ceramide pools, which would otherwise
prove cytotoxic, via conversion to a more benign GSL format such
as Gb3 [38]. Excessive GCS expression has been detected as a
cause of drug resistance in a multitude of cancer cell lines [39].Silencing GCS expression or inhibition of GCS activity sensitized
these resistant cells to more than 20 anticancer agents of diverse
types including cisplatin. Introduction of the GCS gene into drug-
sensitive cells confers cellular resistance to several drugs, in most,
but not to all tested cell lines, indicating that drug resistance to
E X P E R I M E N T A L C E L L R E S E A R C H 3 3 6 ( 2 0 1 5 ) 2 3 – 3 230some extent is cell-type or cancer-dependent [39]. However, this
mechanism has hitherto not been tested in MPM or lung cancer.
MDR1 has been proposed as a speciﬁc glucosylceramide transpor-
ter for the molecule across the Golgi to deliver it for the synthesis of
GSLs [22]. Tumour chemotherapy increases cell stress and generates
ceramide which drives cells to proliferation arrest and apoptosis but
in addition also transactivates GCS expression via the Sp1 transcrip-
tion factor leading to globo-series GSLs (e.g. globotriaosylceramide
Gb3) increase which in turn activates cSrc kinases, and thereby
increases nuclear β-catenin and transactivates MDR1 gene expression.
In MDR1-MDCK cells, cell surface MDR1 co-localized with globo-
triaosylceramide (Gb3) and a soluble analog of Gb3 proved to be an
MDR1 inhibitor [23]. Ceramide as well as the GSLs therefore up-
regulate GCS and MDR1 expressions in response to anticancer drugs,
and confer acquired tumour cell resistance by preventing ceramide-
induced apoptosis and possibly MDR1-mediated drug efﬂux [14,26].
Inhibitors of GCS may therefore be useful in preventing chemotherapy
resistance [22,23].
We have previously demonstrated that Gb3 expression was
signiﬁcantly increased on the cell surface of MPM and NSCLC cell
sublines with acquired cisplatin resistance [26]. In the present
study, cell surface Gb3 expression was increased in a large fraction
of the resistant subline cells and MDR1 was co-expressed in only a
minute fraction of cells noted by ﬂow cytometry whereas MRP1
cell surface expression was not detected. PPMP, almost eradicated
the induced cell surface Gb3-expression in resistant subline cells
whereas cell surface MDR1 expression was reduced only in H1299
cells. It is noteworthy that silencing of Gb3 with PPMP augmented
the sensitivity to cisplatin in cisplatin-resistant MPM subline cells
possibly back to the cisplatin sensitivity of the parental cells as we
previously demonstrated [27]. MDR1 expression was only
decreased by cyclosporin in H1299. This was also the only cell
line where a decreased Gb3 expression was noted following
cyclosporin incubation, indicating that MDR1 might have a role
in the extracellular expression of Gb3 in these cells.
The bacterial toxin verotoxin-1 exerts its cytotoxicity by target-
ing cell surface Gb3, which is the functional receptor of verotoxin-
1 [40]. Combination of cisplatin and subtoxic concentrations of
verotoxin-1 led to a super-additive increase of cytotoxicity and
TUNEL staining, especially in the cisplatin-resistant cell sublines
[27]. Verotoxin-1-Gb3 binding results in internalization, retro-
grade transport via endosomes, TGN, and Golgi to the ER [40,41].
Here the proteolytically cleaved A1 subunit is translocated to the
cytosol to inactivate protein synthesis by depurination of the 28S
RNA of the 60S ribosomal subunit [42]. Cellular glucosylceramide
is required to maintain Gb3 in verotoxin-1-detectable plasma
membrane lipid rafts [16], and is also required for ER retrograde
transport of verotoxin-1. Cells without lipid raft expression of Gb3
are thus insensitive to VT-1 [16].
Cell surface Gb3 but less likely MDR1, but not MRP1 up-
regulation seems to be required for drug resistance to cisplatin
in MPM and NSCLC cells. This means that cell surface Gb3 could
be an important resistance determinant and that the correlation
to MDR1 is of less importance to acquired cisplatin resistance in
MPM and NSCLC. This may however vary with the tumour type or
cell line studied, as several reports suggest that cells which
overexpress MDR1 have higher levels of speciﬁc glycosphingoli-
pids compared to their parental sensitive cells [25,43–46]. Inhibi-
tion of GSL biosynthesis results in the loss of drug resistance and
decreased expression of MDR1 [21,47]. In addition, newlysynthesized Gb3 seems important for verotoxin toxicity which
might indicate that Gb3 expressed as a consequence of acquired
cisplatin resistance might be more important for conveying
cytotoxicity than intrinsically expressed Gb3 [48].
MDR1-mediated glucosylceramide ﬂipping within the Golgi is a
primary mechanism by which glucosylceramide is provided as a
substrate for the various luminal glucosyl transferases involved in
neutral GSL biosynthesis [22]. In addition to the interaction of
MDR1 with glucosylceramide, cell surface MDR1 was found to be
partially co-localized with Gb3 in MDR1 transfected cells [21].
Inhibition of GSL biosynthesis resulted in the loss of drug
resistance and of cell surface MDR1. In MDR1-MDCK cells, cell
surface MDR1 co-localized with globotriaosyl ceramide (Gb3), and
a soluble analog of Gb3 proved an MDR1 inhibitor [23]. MDR1 and
GCS have been shown to be coincidently overexpressed in several
drug-resistant cell lines [14,49]. Localization of MDR1/PgP in
intracellular membranes has also been reported [50–52]. Its
expression on the nuclear membrane has been associated with
extrusion of drugs from the nucleus of multidrugresistant cells
[52,53]. There was no sign of colocalization in any cell line. This
indicates that co-localization of Gb3 with MDR1 was without
signiﬁcance for cisplatin resistance development or for the re-
sensitation of the resistant NSCLC or MPM cell sublines to
cisplatin with PPMP.6. Conclusions
Taken together, these results demonstrate that GCS as reﬂected by
ensuing Gb3 expression might have a regulatory role in acquired
cisplatin drug resistance in NSCLC and MPM cells. Inhibition of
GCS or direct verotoxin-1 targeting of over-expressed cell surface
Gb3 could be efﬁcient approach to reverse acquired cisplatin
resistance of non-small cell lung cancer and malignant pleural
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